Climb Bio Inc

CLYM10 Dec 2024
Healthcare
$3.07
+0.05 (+4.64%)
Lowest Today
$3.05
Highest Today
$3.18
Today’s Open
$3.07
Prev. Close
$3.02
52 Week High
$11.55
52 Week Low
$2.35
To Invest in Climb Bio Inc

Climb Bio Inc

Healthcare
CLYM10 Dec 2024
+0.05 (+4.64%)
1M
3M
6M
1Y
5Y
Low
$3.05
Day’s Range
High
$3.18
3.05
52 Week Low
$2.35
52-Week Range
52 Week High
$11.55
2.35
1 Day
-
1 Week
-7.79%
1 month return
-20.65%
3 month return
-39.7%
6 month return
-39.7%
1 Year return
-
3 Years return
-
5 Years return
-
10 Years return
-
Fundamentals
Market Cap
0
PB Ratio
0
PE Ratio
0
Enterprise Value
0
Total Assets
110.47 mln
Volume

Fund house & investment objective

Company Information
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Organisation
Climb Bio Inc
Employees
9
Industry
Biotechnology
CEO
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities